Vitality Watch

Dossier pubmed review 31-mar-2026
Narrative review or expert overview without new data

Reprogramming the mitochondrial-circadian energy code with incretins.

Key claim: Incretin receptor agonists may serve as systemic geroprotectors by restoring mitochondrial efficiency and circadian alignment, especially when combined with senolytics, NAD+ support, and chrono-entrainment.

Abstract

Mitochondrial dysfunction, circadian disruption, and the accumulation of senescent cells converge to impair metabolic flexibility, a unifying phenotype of obesity and aging. We frame obesity as a nutrient-driven and aging as a time-driven expression of a disrupted mitochondrial-circadian energy code, with shared outputs: impaired substrate switching and flattened energy rhythms. This opinion argues that restoring code integrity, indexed clinically by gains in metabolic flexibility, should guide therapy. Beyond appetite and glycemia, GLP-1 (glucagon-like peptide-1) and dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) agonists may enhance mitochondrial efficiency, support circadian alignment, and temper prosenescent signaling across target tissues (muscle, liver, adipose, islets, and brain). We outline how node-specific and combination strategies (senolytics/senomorphics, mitophagy/NADsupport, and chrono-entrainment) could reprogram systemic energy coordination, improve durability of response, and delay age-related metabolic decline.

Why this matters

The review extends the AOM-as-longevity framing into multi-intervention cocktails through a proposed mitochondrial-circadian framework [mechanism-plausible], rather than new outcome evidence. As an interpretive synthesis [expert-opinion], it establishes neither human geroprotection nor the safety or added benefit of these combinations, and supplies no new media/community evidence that the framing is spreading.

Source

Link

Briefing card

Reprogramming the mitochondrial-circadian energy code with incretins.
Stage: review · pubmed · 31-mar-2026

If you use an incretin drug alongside NAD+ supplements or senolytics for longevity, this review does not demonstrate that the combination improves healthspan or lifespan.

Incretin receptor agonists may serve as systemic geroprotectors by restoring mitochondrial efficiency and circadian alignment, especially when combined with senolytics, NAD+ support, and chrono-entrainment.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.tem.2026.02.011

build build 880 · 2bcef25 · 2026-11-18